Evidence map›Paper›PMID 40717135›Full record

ArticleScientific reports2025

A visualized machine learning model using noninvasive parameters to differentiate men with and without prostatic carcinoma before biopsy.

Wenting Zhou, Linhui Wang, Xue Zhang, Xiaohong Zou, Xuemei Du, Liru Luo, Xiaolan Ye, Shujing Li, Hong Lv, Yuanfu Liu and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenting ZhouDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China.
Linhui WangDepartment of General Practice, Tong'an Community Health Service Center in Longquanyi District, Chengdu, China.
Xue ZhangDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China.
Xiaohong ZouDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China.
Xuemei DuDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China.
Liru LuoDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China.
Xiaolan YeDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China.
Shujing LiDepartment of Urinary and Neohropathy Center, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hong LvDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China. 274299593@qq.com.
Yuanfu LiuDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, 610100, China. 35813402@qq.com.
Xiaoyang Huang, Shenzhen, 518110, China. 2972153045@qq.com.

Funding

Chengdu Medical Research Project 2021242
6 · The paper itself

Abstract

This study aimed to create a visualized extreme gradient boosting (XGBOOST) model to distinguish prostatic carcinoma (PCA) from non-PCA using noninvasive prebiopsy parameters before biopsy. This was a cross-sectional study of 310 Chinese men who underwent prostate biopsy and were divided into PCA (n = 126) and non-PCA (n = 184) groups. The non-PCA patients were diagnosed with benign prostatic hyperplasia (BPH) based on biopsy results. The XGBOOST model was used to analyze 15 noninvasive prebiopsy parameters. The model performance was assessed by the area under the receiver operating characteristic curve (AUC) and compared with four other machine learning models (decision tree learning, lasso, neural network (NNET), and support vector machine (SVM)) and a logistic model. The logistic model identified serum thymidine kinase 1 (STK1p), total prostate-specific antigen (TPSA), and age as key prognostic factors. In the Lasso procedure, free prostate-specific antigen (FPSA) and free-to-total prostate-specific antigen (FTPSA) were also added to machine learning models. The XGBOOST model achieved an AUC of 0.965, which was significantly greater than those of other models (AUC = 0.708-0.817) and the logistic model (AUC = 0.813) (P < 0.001). The 49 decision trees generated by the XGBOOST model were visualized to aid in decision making. This study successfully developed a visualized XGBOOST model with high accuracy in differentiating PCA from non-PCA using eight noninvasive predictors. This model could aid in the precise selection of high-risk PCA patients for biopsy, potentially minimizing unnecessary procedures and their associated costs.

Indexed as

Machine LearningProstatic NeoplasmsAgedBiopsyCross-Sectional StudiesHumansLogistic ModelsMaleMiddle AgedNeural Networks, ComputerProstateProstate-Specific AntigenProstatic HyperplasiaROC CurveProstate-Specific AntigenMachine learningProstatic hyperplasiaProstatic neoplasmsRisk assessmentThymidine kinase 1

Identifiers

PMID40717135
PMCPMC12301460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.